Clinical Trial Update: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL [Phase 2]

View source ↗

Summary

Phase II trial update examining tirelizumab with the R2-ICE regimen for relapsed/refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• R2-ICE
• Tirelizumab (tirelizumab)

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma | Phase 2 | Status: UNKNOWN